COST- EFFECTIVENESS ANALYSIS OF APIXABANO VS. ENOXAPARIN IN THE THROMBOEMBOLISM IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ARTHROPLASTY ELECTIVE THE HIP OR KNEE
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.25756/rpf.v4i4.60 |
Resumo: | This research paper summarizes the results of the cost-effectiveness study of apixaban vs enoxaparin, in the prevention of venous thromboembolism, after knee and hip orthopedic surgery. The cost-effectiveness analysis, performed assuming the National Health System perspective, and considering a time horizon of three months, adopted an analytical decision model in the form of a decision three. The data associated with clinical effectiveness was retrieved from prospective, controlled clinical trials, that compared head-to-head apixaban and enovaparin. Clinical practice and resource use were derived from literature, and validated with an clinical expert. The unit cost associated to the health resources was based in official data sources from the Portuguese Health Ministry (Portaria nº 839-A/2009, de 31 de julho; INFARMED; and ACSS). For knee replacement therapy, apixaban was the dominant option, when compared to enoxaparin. Apixaban was a dominant alternative when compared with Enoxaparin for both types of orthopedic surgery. |
id |
RCAP_ba4feacf426682f8e143d28acb269f04 |
---|---|
oai_identifier_str |
oai:ojs.farmacoterapia.pt:article/60 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
COST- EFFECTIVENESS ANALYSIS OF APIXABANO VS. ENOXAPARIN IN THE THROMBOEMBOLISM IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ARTHROPLASTY ELECTIVE THE HIP OR KNEEANÁLISE DE CUSTO-EFETIVIDADE DO APIXABANO VS. ENOXAPARINA NA PREVENÇÃO DO TROMBOEMBOLISMO VENOSO APÓS ARTROPLASTIA ELETIVA DA ANCA OU JOELHOThis research paper summarizes the results of the cost-effectiveness study of apixaban vs enoxaparin, in the prevention of venous thromboembolism, after knee and hip orthopedic surgery. The cost-effectiveness analysis, performed assuming the National Health System perspective, and considering a time horizon of three months, adopted an analytical decision model in the form of a decision three. The data associated with clinical effectiveness was retrieved from prospective, controlled clinical trials, that compared head-to-head apixaban and enovaparin. Clinical practice and resource use were derived from literature, and validated with an clinical expert. The unit cost associated to the health resources was based in official data sources from the Portuguese Health Ministry (Portaria nº 839-A/2009, de 31 de julho; INFARMED; and ACSS). For knee replacement therapy, apixaban was the dominant option, when compared to enoxaparin. Apixaban was a dominant alternative when compared with Enoxaparin for both types of orthopedic surgery.Este artigo apresenta os resultados de um estudo de custo-efetividade do apixabano versus enoxaparina na prevenção do tromboembolismo venoso após cirurgia ortopédica da anca e do joelho. O estudo de avaliação económica, conduzido na perspetiva do Serviço Nacional de Saúde, com um horizonte temporal de três meses, adotou um modelo analítico na forma de uma árvore de decisão. Os dados de efetividade clínica foram recolhidos a partir de estudos experimentais prospetivos e controlados, que comparavam diretamente as alternativas em análise, tendo os dados de consumo de recursos sido obtidos a partir da bibliografia disponível, bem como a partir da consulta a peritos. O custo unitário dos recursos foi obtido a partir da Tabela Nacional dos Grupos de Diagnóstico Homogéneos (Portaria n.º 839-A/2009, de 31 de julho) e do catálogo da Administração Central da Sistema de Saúde (ACSS). O apixabano foi a alternativa dominante quando comparado com a enoxaparina, tendo-se verificado esta dominância para ambos os tipos de cirurgia analisados – PTA e PTJ.Formifarma2012-12-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25756/rpf.v4i4.60https://doi.org/10.25756/rpf.v4i4.60Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 4 No 4 (2012): Outubro; 4-14Revista Portuguesa de Farmacoterapia; v. 4 n. 4 (2012): Outubro; 4-142183-73411647-354Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://revista.farmacoterapia.pt/index.php/rpf/article/view/60http://revista.farmacoterapia.pt/index.php/rpf/article/view/60/48Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapiahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessLourenço, ÓscarBatel-Marques, FranciscoCarrasco, JoãoInês, Mónica2023-09-01T04:33:10Zoai:ojs.farmacoterapia.pt:article/60Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:11:31.974079Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
COST- EFFECTIVENESS ANALYSIS OF APIXABANO VS. ENOXAPARIN IN THE THROMBOEMBOLISM IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ARTHROPLASTY ELECTIVE THE HIP OR KNEE ANÁLISE DE CUSTO-EFETIVIDADE DO APIXABANO VS. ENOXAPARINA NA PREVENÇÃO DO TROMBOEMBOLISMO VENOSO APÓS ARTROPLASTIA ELETIVA DA ANCA OU JOELHO |
title |
COST- EFFECTIVENESS ANALYSIS OF APIXABANO VS. ENOXAPARIN IN THE THROMBOEMBOLISM IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ARTHROPLASTY ELECTIVE THE HIP OR KNEE |
spellingShingle |
COST- EFFECTIVENESS ANALYSIS OF APIXABANO VS. ENOXAPARIN IN THE THROMBOEMBOLISM IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ARTHROPLASTY ELECTIVE THE HIP OR KNEE Lourenço, Óscar |
title_short |
COST- EFFECTIVENESS ANALYSIS OF APIXABANO VS. ENOXAPARIN IN THE THROMBOEMBOLISM IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ARTHROPLASTY ELECTIVE THE HIP OR KNEE |
title_full |
COST- EFFECTIVENESS ANALYSIS OF APIXABANO VS. ENOXAPARIN IN THE THROMBOEMBOLISM IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ARTHROPLASTY ELECTIVE THE HIP OR KNEE |
title_fullStr |
COST- EFFECTIVENESS ANALYSIS OF APIXABANO VS. ENOXAPARIN IN THE THROMBOEMBOLISM IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ARTHROPLASTY ELECTIVE THE HIP OR KNEE |
title_full_unstemmed |
COST- EFFECTIVENESS ANALYSIS OF APIXABANO VS. ENOXAPARIN IN THE THROMBOEMBOLISM IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ARTHROPLASTY ELECTIVE THE HIP OR KNEE |
title_sort |
COST- EFFECTIVENESS ANALYSIS OF APIXABANO VS. ENOXAPARIN IN THE THROMBOEMBOLISM IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ARTHROPLASTY ELECTIVE THE HIP OR KNEE |
author |
Lourenço, Óscar |
author_facet |
Lourenço, Óscar Batel-Marques, Francisco Carrasco, João Inês, Mónica |
author_role |
author |
author2 |
Batel-Marques, Francisco Carrasco, João Inês, Mónica |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Lourenço, Óscar Batel-Marques, Francisco Carrasco, João Inês, Mónica |
description |
This research paper summarizes the results of the cost-effectiveness study of apixaban vs enoxaparin, in the prevention of venous thromboembolism, after knee and hip orthopedic surgery. The cost-effectiveness analysis, performed assuming the National Health System perspective, and considering a time horizon of three months, adopted an analytical decision model in the form of a decision three. The data associated with clinical effectiveness was retrieved from prospective, controlled clinical trials, that compared head-to-head apixaban and enovaparin. Clinical practice and resource use were derived from literature, and validated with an clinical expert. The unit cost associated to the health resources was based in official data sources from the Portuguese Health Ministry (Portaria nº 839-A/2009, de 31 de julho; INFARMED; and ACSS). For knee replacement therapy, apixaban was the dominant option, when compared to enoxaparin. Apixaban was a dominant alternative when compared with Enoxaparin for both types of orthopedic surgery. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-12-28 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.25756/rpf.v4i4.60 https://doi.org/10.25756/rpf.v4i4.60 |
url |
https://doi.org/10.25756/rpf.v4i4.60 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://revista.farmacoterapia.pt/index.php/rpf/article/view/60 http://revista.farmacoterapia.pt/index.php/rpf/article/view/60/48 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Formifarma |
publisher.none.fl_str_mv |
Formifarma |
dc.source.none.fl_str_mv |
Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 4 No 4 (2012): Outubro; 4-14 Revista Portuguesa de Farmacoterapia; v. 4 n. 4 (2012): Outubro; 4-14 2183-7341 1647-354X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799129986075983872 |